Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGMN | Q99538 | 4/20 | 0.61 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | THRB | P10828 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | GAK | O14976 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | INSR | P06213 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL375344 | 0.98 | LGMN (0.59) | LGMNCHEK1JAK2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3402782 | 0.98 | LGMN (0.59) | LGMNCHEK1JAK2MEN1KMT2A | |
| SCHEMBL2731784 | 0.94 | CHEK1 (0.55) | LGMNCHEK1JAK2MEN1KMT2A | |
| SCHEMBL14180536 | 0.89 | CHEK1 (0.51) | LGMNCHEK1JAK2MEN1KMT2A | |
| SCHEMBL15358736 | 0.88 | ALDH1A1 (0.53) | LGMNCHEK1JAK2MEN1KMT2A | |
| SCHEMBL1232770 | 0.87 | LGMN (0.57) | LGMNCHEK1JAK2MEN1KMT2A | |
| SCHEMBL521335 | 0.86 | CHEK1 (0.49) | LGMNCHEK1JAK2MEN1KMT2A | |
| SCHEMBL310378 | 0.86 | CHEK1 (0.47) | LGMNCHEK1JAK2MEN1KMT2A | |
| SCHEMBL14180540 | 0.85 | HSD17B10 (0.50) | LGMNCHEK1JAK2MEN1KMT2A | |
| SCHEMBL13362137 | 0.85 | AKR1C3 (0.66) | CHEK1ALDH1A1MAPTCYP2C19GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 419 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200276194-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2020-09-03 | — | — | US | claimed |
| CN-109516977-B | Anilinopyrimidine/quinoline heterocomplex, preparation method and medical application | 长治学院 | 2020-01-10 | — | — | CN | claimed |
| US-10434101-B2 | Heterocyclic compounds and uses thereof | CELGENE CAR LLC (BM) | 2019-10-08 | — | — | US | claimed |
| EP-2507243-B1 | SPIROINDOLINONE PYRROLIDINES | HOFFMANN LA ROCHE (CH) | 2015-06-10 | — | — | EP | claimed |
| EP-2507243-A1 | SPIROINDOLINONE PYRROLIDINES | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | claimed |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | US | claimed |
| US-6812225-B2 | PYSCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | ASTRAZENECA AB (SE) | 2004-11-02 | — | — | US | claimed |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | claimed |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260103455-A1 | ULK3 INHIBITORS AND USES THEREOF | H LEE MOFFITT CANCER CT & RES (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4168399-B1 | COMPOUNDS AND THEIR USES AS MIF INHIBITORS | NANJING IMMUNOPHAGE BIOMEDICAL CO LTD (CN) | 2026-04-01 | — | — | EP | disclosed |
| EP-3508204-B1 | QUINAZOLIN-8-YL DERIVATIVES FOR USE IN METHODS OF TREATING MELANOMA, NON-SMALL CELL LUNG CANCER, THYROID CANCER, OVARIAN CANCER, OR COLON CANCER | NEUPHARMA INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12466812-B2 | Pyridinyltriazine derivative having protein kinase inhibitory activity, and pharmaceutical composition for preventing, ameliorating, or treating cancer comprising same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2025-11-11 | — | — | US | disclosed |
| WO-2002055012-A2 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055013-A2 | THERAPEUTIC CHROMONE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055014-A2 | THERAPEUTIC CHROMAN COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| EP-0803063-A4 | METHODS FOR PRODUCTION OF LARGE CATALOGUED CHEMICAL LIBRARIES | PANLABS INC (US) | 1998-04-29 | — | — | EP | disclosed |
| EP-0803063-A1 | METHODS FOR PRODUCTION OF LARGE CATALOGUED CHEMICAL LIBRARIES | PANLABS INCORPORATED (US) | 1997-10-29 | — | — | EP | disclosed |
| WO-1996021859-A1 | METHODS FOR PRODUCTION OF LARGE CATALOGUED CHEMICAL LIBRARIES | PANLABS, INC. (US) | 1996-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | LGMN 4781/4885CHEK1 523/4885JAK2 266/4885 |
| US-10434101-B2 | Heterocyclic compounds and uses thereof | ABCG2, CYP3A5, CYP3A43 | LGMN 2036/4885CHEK1 2288/4885JAK2 183/4885 |
| US-20200276194-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | LGMN 2036/4885CHEK1 2288/4885JAK2 183/4885 |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | HTR1B, HTR1D, HTR1A | LGMN 3896/4885CHEK1 3029/4885JAK2 1623/4885 |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | HTR1A, HTR1D, HTR1B | LGMN 3944/4885CHEK1 3136/4885JAK2 1384/4885 |
| US-12466812-B2 | Pyridinyltriazine derivative having protein kinase inhibitory activity, and pharmaceutical composition for preventing, ameliorating, or treating cancer comprising same | FGFR3, FGFR1, FGFR4 | LGMN 4715/4885CHEK1 171/4885JAK2 91/4885 |
| US-20260103455-A1 | ULK3 INHIBITORS AND USES THEREOF | ULK3, ULK1, ULK2 | LGMN 2500/4885CHEK1 67/4885JAK2 2451/4885 |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | BRAF, TTK, MAP4K2 | LGMN 4735/4885CHEK1 117/4885JAK2 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.